Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

Background Studies showed that vascular endothelial growth factor (VEGF) inhibitors could improve therapeutic efficacy of PD-1/PD-L1 antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immunoresponsive TME. Ivonescimab is a first-in-class, humanized tetravalent bisp...

Full description

Bibliographic Details
Main Authors: Wenjing Wang, Yu Xia, Charlotte Lemech, Adnan Nagrial, Baiyong Li, Zhongmin Maxwell Wang, Sophia Frentzas, Anna Rachelle Austria Mislang, Craig Underhill, Jermaine I G Coward
Format: Article
Language:English
Published: BMJ Publishing Group 2024-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/4/e008037.full

Internet

https://jitc.bmj.com/content/12/4/e008037.full

Similar Items